Everything below concerns 反相色谱. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-06. Numbers and descriptions here follow the published literature rather than marketing material.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
== Side effects == Some side effects are hypoglycemia (low blood sugar), hypokalemia (low blood potassium), and allergic reactions. Allergy to insulin affected about 2% of people, of which most reactions are not due to the insulin itself but to preservatives added to insulin such as zinc, protamine, and meta-cresol. Most reactions are Type I hypersensitivity reactions and rarely cause anaphylaxis. A suspected allergy to insulin can be confirmed by skin prick testing, patch testing and occasionally skin biopsy. First line therapy against insulin hypersensitivity reactions include symptomatic therapy with antihistamines. The affected persons are then switched to a preparation that does not contain the specific agent they are reacting to or undergo desensitization. Cutaneous adverse effects Other side effects may include pain or skin changes at the sites of injection. Repeated subcutaneous injection without site rotation can lead to lipohypertrophy and amyloidomas, which manifest as firm palpable nodules under the skin.
=== Diagnostics === PAH is useful for the measurement of renal plasma flow. The renal extraction ratio of PAH in a normal individual is approximately 0.92. This means that unlike inulin and creatinine, which are filtered in the glomerulus and ignored by the rest of the kidney, aminohippuric acid is both filtered and secreted, being almost entirely removed from the bloodstream in a normal kidney.
== Methodology == To ensure consistency and repeatability, the methods use in the chemical analysis of water samples are often agreed and published at a national or state level. By convention these are often referred to as "Blue book". Certain analyses are performed in-field (e.g. pH, specific conductance) while others involve sampling and laboratory testing. The methods defined in the relevant standards can be broadly classified as:
Sources: en.wikipedia.org
== External links == Asadzadeh, Afsoon; Pakkhoo, Saba; Saeidabad, Mahsa Mirzaei; Khezri, Hero; Ferdousi, Reza (1 January 2020). "Information technology in emergency management of COVID-19 outbreak". Informatics in Medicine Unlocked. 21 100475. doi:10.1016/j.imu.2020.100475. ISSN 2352-9148. PMC 7661942. PMID 33204821., a scientific review for an overview of how IT applications could be used during the COVID-19 outbreak and pandemic
or greater and depend on impurity concentration. Near zero carrier density, graphene exhibits positive photoconductivity and negative photoconductivity at high carrier density, governed by the interplay between photoinduced changes of both the Drude weight and the carrier scattering rate. Graphene doped with various gaseous species (both acceptors and donors) can be returned to an undoped state by gentle heating in a vacuum. Even for dopant concentrations in excess of 1012 cm−2, carrier mobility exhibits no observable change. Graphene doped with potassium in ultra-high vacuum at low temperature can reduce mobility 20-fold. The mobility reduction is reversible on heating the graphene to remove the potassium. Due to graphene's two dimensions, charge fractionalization (where the apparent charge of individual pseudoparticles in low-dimensional systems is less than a single quantum) is thought to occur. It may therefore be a suitable material for constructing quantum computers using anyonic circuits.
== External links == Angiogenesis for Heart Disease from Angioplasty.Org Angiogenesis - The Virtual Library of Biochemistry, Molecular Biology and Cell Biology Visualizing Angiogenesis with GFP NCI Understanding Cancer series on Angiogenesis
Sources: en.wikipedia.org
=== EC 2.8.2: Sulfotransferases === EC 2.8.2.1: aryl sulfotransferase EC 2.8.2.2: alcohol sulfotransferase EC 2.8.2.3: amine sulfotransferase EC 2.8.2.4: estrone sulfotransferase EC 2.8.2.5: chondroitin 4-sulfotransferase EC 2.8.2.6: choline sulfotransferase EC 2.8.2.7: UDP-N-acetylgalactosamine-4-sulfate sulfotransferase EC 2.8.2.8: [heparan sulfate]-glucosamine N-sulfotransferase EC 2.8.2.9: tyrosine-ester sulfotransferase EC 2.8.2.10: Renilla-luciferin sulfotransferase EC 2.8.2.11: galactosylceramide sulfotransferase EC 2.8.2.12: deleted, identical to EC 2.8.2.8, [heparan sulfate]-glucosamine N-sulfotransferase EC 2.8.2.13: psychosine sulfotransferase EC 2.8.2.14: bile salt sulfotransferase EC 2.8.2.15: steroid sulfotransferase EC 2.8.2.16: thiol sulfotransferase EC 2.8.2.17: chondroitin 6-sulfotransferase EC 2.8.2.18: cortisol sulfotransferase EC 2.8.2.19: triglucosylalkylacylglycerol sulfotransferase EC 2.8.2.20: protein-tyrosine sulfotransferase EC 2.8.2.21: keratan sulfotransferase EC 2.8.2.22: aryl-sulfate sulfotransferase EC 2.8.2.23: [heparan sulfate]-glucosamine 3-sulfotransferase 1 EC 2.8.2.24: desulfoglucosinolate sulfotransferase EC 2.8.2.25: flavonol 3-sulfotransferase EC 2.8.2.26: quercetin-3-sulfate 3′-sulfotransferase EC 2.8.2.27: quercetin-3-sulfate 4′-sulfotransferase EC 2.8.2.28: quercetin-3,3′-bissulfate 7-sulfotransferase EC 2.8.2.29: [heparan sulfate]-glucosamine 3-sulfotransferase 2 EC 2.8.2.30: [heparan sulfate]-glucosamine 3-sulfotransferase 3 EC 2.8.2.31: petromyzonol sulfotransferase EC 2.8.2.32: scymnol sulfotransferase EC 2.8.2.33: N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase EC 2.8.2.34: glycochenodeoxycholate sulfotransferase EC 2.8.2.35: dermatan 4-sulfotransferase EC 2.8.2.36: desulfo-A47934 sulfotransferase EC 2.8.2.37: trehalose 2-sulfotransferase EC 2.8.2.38: aliphatic desulfoglucosinolate sulfotransferase EC 2.8.2.39: hydroxyjasmonate sulfotransferase EC 2.8.2.40: ω-hydroxy-β-dihydromenaquinone-9 sulfotransferase
== See also == NMR spectroscopy Nuclear magnetic resonance Nuclear magnetic resonance spectroscopy of carbohydrates Nuclear magnetic resonance spectroscopy of nucleic acids Protein crystallization Protein dynamics Relaxation (NMR) X-ray crystallography
=== Natural disasters and conservation === Kennedy has advocated for natural disaster aid for Louisiana to address hurricane damage as a member of the Appropriations Committee. He worked to reform the National Flood Insurance Program because he believes flood insurance is too expensive for coastal communities, including those in Louisiana. In 2023, Kennedy called on FEMA to disclose the algorithm it uses to determine flood insurance prices after premiums increased rapidly under FEMA's Risk Rating 2.0, saying, "Since millions of Louisianians depend on the NFIP to protect their homes from natural disasters, FEMA must come clean about why premiums are skyrocketing under Risk Rating 2.0. In the meantime, my bills would ensure fairer rates for the people of Louisiana." As treasurer, Kennedy believed in investing in coastal restoration and conservation. He worked to ensure that settlement money from the BP oil spill was used for coastal protection and restoration. Kennedy also fought to protect tobacco settlement money that had been allocated toward coastal restoration after the governor proposed using the money to cover other state debts.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。